News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–14
Matches
14
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

14 matching headlines

Ticker or company: SPTXMain company stories
Clear
Latest

MarketBeat Earnings

Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High - Here's What Happened

Seaport Therapeutics (NASDAQ:SPTX) reached a new 52-week high of $25.07, closing at $24.40 with a market capitalization of $1.31 billion. This surge follows largely positive analyst initiations, although the company reported a quarterly loss exceeding consensus estimates. Insider buying by director Robert J. Hombach and a significant new stake by institutional investor TRV GP VI LLC further highlight …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
Just inNext headlines
Stock Titan Deals and strategy Main company 🇺🇸 United States

PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake

PureTech Health plc, along with its affiliates, has reported a beneficial ownership of 31.2% in Seaport Therapeutics, Inc., amounting to 16,685,013 shares of Voting Common Stock. This stake is held by PureTech LYT, Inc., with PureTech Health LLC and PureTech Health plc exercising indirect …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Earnings Main company 🇺🇸 United States

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages

Seaport Therapeutics, Inc. (NASDAQ:SPTX) has received an average "Hold" recommendation from nine brokerages, with an average 12-month price target of $38.40. The company recently reported a quarterly loss of $1.78 per share, missing consensus estimates, and analysts expect a full-year loss of approximately $4.60 …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Seaport Therapeutics (SPTX) insider Steven M. Paul reports 6.3% stake

Steven M. Paul has reported a 6.3% stake in Seaport Therapeutics, Inc. (SPTX) through a Schedule 13G SEC filing. This ownership amounts to 3,516,718 shares of Voting Common Stock, comprising both shares held directly and shares from exercisable stock options. Paul maintains sole voting …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Seaport Therapeutics (SPTX): Daphne Zohar discloses 5.23M-share, 9.1% beneficial stake

Daphne Zohar has reported a beneficial stake of 9.1% in Seaport Therapeutics (SPTX), totaling 5,225,497 shares of Voting Common Stock as of June 30, 2026. This ownership includes both shares held of record and stock options exercisable within 60 days, giving her sole voting …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Seaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary

Seaport Therapeutics, Inc. reported its second-quarter 2026 results, showing no product revenue and a net loss of $(62.6)M, or diluted EPS of $(1.78), a significant increase from the previous year's loss. The company highlighted clinical progress with its GlyphAllo and GlyphAgo programs, with key …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX

Seaport Therapeutics reported its second-quarter research and development expenses were $24.6 million. This financial detail is key for understanding the company's operational spending.

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

SPTX Stock Price and Chart — NASDAQ:SPTX

This article provides an overview of Seaport Therapeutics, Inc. (SPTX) stock on NASDAQ, detailing its current price, performance across various timeframes, and key financial statistics. It includes information on market capitalization, recent earnings, employee data, company details, and analyst ratings, alongside answers to frequently …

SPTX main company
Sharemaestro market context Stored weekly price path 16 weeks +22.1% · Next-week setup positive 62.0% SPTX stored weekly price path from 1 May 2026 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context